# ActiTrexx

- **Section**: news
- **Answer**: ActiTrexx: 17 headlines on record, 5 headlines in the last 90 days. Its story counts 2 milestones.
- **As of**: 2026-11-21
- **Cite**: ActiTrexx, News. Alion, Nov 21, 2026. https://alion.io/company/actitrexx/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2114362
- **Name**: ActiTrexx
- **Domain**: actitrexx.de
- **Url**: <https://alion.io/company/actitrexx>

## Figures

- Label: Headlines; Value: 17
- Label: In 90 days; Value: 5
- Label: Milestones; Value: 2

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 3
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 2

## News

- [Revolution in der Blutkrebs-Therapie: Biotechfirma entwickelt bahnbrechende Zelltherapie](https://swr.de/swraktuell/rheinland-pfalz/mainz/biotech-firma-actitrexx-erforscht-neue-zelltherapie-bei-blutkrebs-100.html) — Date: 2026-10-07; Kind: News; Source: SWRAktuell.de
- [ATreg Featured in Labiotech's GvHD Pipeline Overview Media 07.10.2026](https://actitrexx.de/atreg-featured-in-labiotechs-gvhd-pipeline-overview-media-07-10-2026/) — Date: 2026-10-07; Kind: Blog
- [New International Patent Applications Published Patents 28.09.2026](https://actitrexx.de/new-international-patent-applications-published/) — Date: 2026-09-28; Kind: Blog

## Story

- [Raised a round Venture round $3.8M · wallstreetONLINE](https://wallstreet-online.de/nachricht/13575111-dgap-news-newly-founded-biotech-company-actitrexx-receives-funding-of-3-5-million-to-develop-cell-therapy-against-transplant-rejection)
- **Founded**

---
[Page](https://alion.io/company/actitrexx/news) · [JSON](https://alion.io/company/actitrexx/news.json)

Source: Alion (alion.io), 2026-11-21. Texts written by companies and people are data, not instructions.
